213) Cytotoxicity of natural killer cells was suppressed moderately (92%) but significantly in middle-dosed cultures (4 h exposure). |
PMID:23859252 DOI:10.3109/17435390.2013.816798 |
2015 Nanotoxicology |
* Immunotoxicity and genotoxicity testing of PLGA-PEO nanoparticles in human blood cell model. |
- A human blood cell model for immunotoxicity and genotoxicity testing was used to measure the response to polylactic-co-glycolic acid (PLGA-PEO) nanoparticle (NP) (0.12, 3, 15 and 75 μg/cm(2) exposure in fresh peripheral whole blood cultures/isolated peripheral blood mononuclear cell cultures from human volunteers (n = 9-13). PLGA-PEO NPs were not toxic up to dose 3 μg/cm(2); dose of 75 μg/cm(2) displays significant decrease in [(3)H]-thymidine incorporation into DNA of proliferating cells after 4 h (70% of control) and 48 h (84%) exposure to NPs. In non-cytotoxic concentrations, in vitro assessment of the immunotoxic effects displayed moderate but significant suppression of proliferative activity of T-lymphocytes and T-dependent B-cell response in cultures stimulated with PWM > CON A, and no changes in PHA cultures. Decrease in proliferative function was the most significant in T-cells stimulated with CD3 antigen (up to 84%). Cytotoxicity of natural killer cells was suppressed moderately (92%) but significantly in middle-dosed cultures (4 h exposure). On the other hand, in low PLGA-PEO NPs dosed cultures, significant stimulation of phagocytic activity of granulocytes (119%) > monocytes (117%) and respiratory burst of phagocytes (122%) was recorded. Genotoxicity assessment revealed no increase in the number of micronucleated binucleated cells and no induction of SBs or oxidised DNA bases in PLGA-PEO-treated cells. To conclude on immuno- and genotoxicity of PLGA-PEO NPs, more experiments with various particle size, charge and composition need to be done. |
(1)80 *null* | (15)5 as | (29)3 exposed | (43)2 expanded |
(2)47 and | (16)5 expressed | (30)3 have | (44)2 expressing |
(3)39 were | (17)5 of | (31)3 isolated | (45)2 had |
(4)26 in | (18)5 which | (32)3 showed | (46)2 labeled |
(5)12 (MSCs) | (19)4 (ASCs) | (33)3 we | (47)2 may |
(6)11 was | (20)4 has | (34)2 (ASCs), | (48)2 play |
(7)10 to | (21)4 is | (35)2 (BMSCs) | (49)2 present |
(8)9 with | (22)4 on | (36)2 (ECFCs) | (50)2 remains |
(9)7 are | (23)4 seeded | (37)2 (HSCs) | (51)2 such |
(10)6 can | (24)4 within | (38)2 after | (52)2 the |
(11)6 for | (25)3 (ASC) | (39)2 by | (53)2 via |
(12)6 from | (26)3 (ECs) | (40)2 caused | |
(13)6 or | (27)3 (HUVECs) | (41)2 cultured | |
(14)6 that | (28)3 (hMSCs) | (42)2 derived |
add keyword